BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27539624)

  • 1. Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.
    Melani C; Roschewski M
    Oncology (Williston Park); 2016 Aug; 30(8):731-8, 744. PubMed ID: 27539624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
    Kwok M; Wu SP; Mo C; Summers T; Roschewski M
    Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.
    Shin SH; Kim YJ; Lee D; Cho D; Ko YH; Cho J; Park WY; Park D; Kim SJ; Kim WS
    Leuk Lymphoma; 2019 Sep; 60(9):2237-2246. PubMed ID: 30774000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
    Wu FT; Lu L; Xu W; Li JY
    Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.
    Roschewski M; Staudt LM; Wilson WH
    Blood; 2016 Jun; 127(25):3127-32. PubMed ID: 27081097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
    Lakhotia R; Roschewski M
    Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
    Kurtz DM; Scherer F; Jin MC; Soo J; Craig AFM; Esfahani MS; Chabon JJ; Stehr H; Liu CL; Tibshirani R; Maeda LS; Gupta NK; Khodadoust MS; Advani RH; Levy R; Newman AM; Dührsen U; Hüttmann A; Meignan M; Casasnovas RO; Westin JR; Roschewski M; Wilson WH; Gaidano G; Rossi D; Diehn M; Alizadeh AA
    J Clin Oncol; 2018 Oct; 36(28):2845-2853. PubMed ID: 30125215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy in non-Hodgkin's lymphoma.
    Melani C; Wilson WH; Roschewski M
    Hematol Oncol; 2019 Jun; 37 Suppl 1():70-74. PubMed ID: 31187522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on Circulating Tumor DNA Assessment in Lymphoma.
    Darrah JM; Herrera AF
    Curr Hematol Malig Rep; 2018 Oct; 13(5):348-355. PubMed ID: 30136210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
    Cherng HJ; Herrera A
    Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Chase ML; Armand P
    Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.
    Melani C; Wilson WH; Roschewski M
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid biopsy of circulating tumor DNA and biosensor applications.
    Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
    Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical applications of circulating tumor DNA in indolent B-cell lymphomas.
    Lakhotia R; Roschewski M
    Semin Hematol; 2023 Jul; 60(3):164-172. PubMed ID: 37419716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.
    Garg S; Kumar A; Gupta R
    Clin Transl Oncol; 2021 Nov; 23(11):2206-2219. PubMed ID: 33991328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance scanning in lymphoma.
    Rutherford SC
    Clin Adv Hematol Oncol; 2019 Jun; 17(6):352-359. PubMed ID: 31437139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
    Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
    Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.